Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895726097> ?p ?o ?g. }
- W2895726097 endingPage "45" @default.
- W2895726097 startingPage "35" @default.
- W2895726097 abstract "Wound infections are the main cause of sepsis in patients with burns and increase burn-related morbidity and mortality. Bacteriophages, natural bacterial viruses, are being considered as an alternative therapy to treat infections caused by multidrug-resistant bacteria. We aimed to compare the efficacy and tolerability of a cocktail of lytic anti-Pseudomonas aeruginosa bacteriophages with standard of care for patients with burns.In this randomised phase 1/2 trial, patients with a confirmed burn wound infection were recruited from nine burn centres in hospitals in France and Belgium. Patients were eligible if they were aged 18 years or older and had a burn wound clinically infected with P aeruginosa. Eligible participants were randomly assigned (1:1) by use of an interactive web response system to a cocktail of 12 natural lytic anti-P aeruginosa bacteriophages (PP1131; 1 × 106 plaque-forming units [PFU] per mL) or standard of care (1% sulfadiazine silver emulsion cream), both given as a daily topical treatment for 7 days, with 14 days of follow-up. Masking of treatment from clinicians was not possible because of the appearance of the two treatments (standard of care a thick cream, PP1131 a clear liquid applied via a dressing), but assignments were masked from microbiologists who analysed the samples and patients (treatment applied while patients were under general anaesthetic). The primary endpoint was median time to sustained reduction in bacterial burden by at least two quadrants via a four-quadrant method, assessed by use of daily swabs in all participants with a microbiologically documented infection at day 0 who were given at least one sulfadiazine silver or phage dressing (modified intention-to-treat population). Safety was assessed in all participants who received at least one dressing according to protocol. Ancillary studies were done in the per-protocol population (all PP1131 participants who completed 7 days of treatment) to assess the reasons for success or failure of phage therapy. This trial is registered with the European Clinical Trials database, number 2014-000714-65, and ClinicalTrials.gov, number NCT02116010, and is now closed.Between July 22, 2015, and Jan 2, 2017, across two recruitment periods spanning 13 months, 27 patients were recruited and randomly assigned to receive phage therapy (n=13) or standard of care (n=14). One patient in the standard of care group was not exposed to treatment, giving a safety population of 26 patients (PP1131 n=13, standard of care n=13), and one patient in the PP1131 group did not have an infection at day 0, giving an efficacy population of 25 patients (PP1131 n=12, standard of care n=13). The trial was stopped on Jan 2, 2017, because of the insufficient efficacy of PP1131. The primary endpoint was reached in a median of 144 h (95% CI 48-not reached) in the PP1131 group versus a median of 47 h (23-122) in the standard of care group (hazard ratio 0·29, 95% CI 0·10-0·79; p=0·018). In the PP1131 group, six (50%) of 12 analysable participants had a maximal bacterial burden versus two (15%) of 13 in the standard of care group. PP1131 titre decreased after manufacturing and participants were given a lower concentration of phages than expected (1 × 102 PFU/mL per daily dose). In the PP1131 group, three (23%) of 13 analysable participants had adverse events versus seven (54%) of 13 in the standard of care group. One participant in each group died after follow-up and the deaths were determined to not be related to treatment. The ancillary study showed that the bacteria isolated from patients with failed PP1131 treatment were resistant to low phage doses.At very low concentrations, PP1131 decreased bacterial burden in burn wounds at a slower pace than standard of care. Further studies using increased phage concentrations and phagograms in a larger sample of participants are warranted.European Commission: Framework Programme 7." @default.
- W2895726097 created "2018-10-12" @default.
- W2895726097 creator A5005379697 @default.
- W2895726097 creator A5006316060 @default.
- W2895726097 creator A5015306524 @default.
- W2895726097 creator A5018059938 @default.
- W2895726097 creator A5031699708 @default.
- W2895726097 creator A5037939253 @default.
- W2895726097 creator A5040119306 @default.
- W2895726097 creator A5041118282 @default.
- W2895726097 creator A5044209745 @default.
- W2895726097 creator A5048044374 @default.
- W2895726097 creator A5060107522 @default.
- W2895726097 creator A5075955953 @default.
- W2895726097 creator A5076347943 @default.
- W2895726097 creator A5079179476 @default.
- W2895726097 creator A5082657255 @default.
- W2895726097 creator A5083457840 @default.
- W2895726097 date "2019-01-01" @default.
- W2895726097 modified "2023-10-14" @default.
- W2895726097 title "Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial" @default.
- W2895726097 cites W1603855872 @default.
- W2895726097 cites W1984007212 @default.
- W2895726097 cites W2025718730 @default.
- W2895726097 cites W2117840807 @default.
- W2895726097 cites W2120327993 @default.
- W2895726097 cites W2123978130 @default.
- W2895726097 cites W2136463291 @default.
- W2895726097 cites W2154244778 @default.
- W2895726097 cites W2230026862 @default.
- W2895726097 cites W2304346766 @default.
- W2895726097 cites W2344766653 @default.
- W2895726097 cites W2621428191 @default.
- W2895726097 cites W2743296461 @default.
- W2895726097 cites W2747615902 @default.
- W2895726097 cites W2769152635 @default.
- W2895726097 cites W2771421273 @default.
- W2895726097 cites W29620779 @default.
- W2895726097 cites W4255578408 @default.
- W2895726097 doi "https://doi.org/10.1016/s1473-3099(18)30482-1" @default.
- W2895726097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30292481" @default.
- W2895726097 hasPublicationYear "2019" @default.
- W2895726097 type Work @default.
- W2895726097 sameAs 2895726097 @default.
- W2895726097 citedByCount "469" @default.
- W2895726097 countsByYear W28957260972018 @default.
- W2895726097 countsByYear W28957260972019 @default.
- W2895726097 countsByYear W28957260972020 @default.
- W2895726097 countsByYear W28957260972021 @default.
- W2895726097 countsByYear W28957260972022 @default.
- W2895726097 countsByYear W28957260972023 @default.
- W2895726097 crossrefType "journal-article" @default.
- W2895726097 hasAuthorship W2895726097A5005379697 @default.
- W2895726097 hasAuthorship W2895726097A5006316060 @default.
- W2895726097 hasAuthorship W2895726097A5015306524 @default.
- W2895726097 hasAuthorship W2895726097A5018059938 @default.
- W2895726097 hasAuthorship W2895726097A5031699708 @default.
- W2895726097 hasAuthorship W2895726097A5037939253 @default.
- W2895726097 hasAuthorship W2895726097A5040119306 @default.
- W2895726097 hasAuthorship W2895726097A5041118282 @default.
- W2895726097 hasAuthorship W2895726097A5044209745 @default.
- W2895726097 hasAuthorship W2895726097A5048044374 @default.
- W2895726097 hasAuthorship W2895726097A5060107522 @default.
- W2895726097 hasAuthorship W2895726097A5075955953 @default.
- W2895726097 hasAuthorship W2895726097A5076347943 @default.
- W2895726097 hasAuthorship W2895726097A5079179476 @default.
- W2895726097 hasAuthorship W2895726097A5082657255 @default.
- W2895726097 hasAuthorship W2895726097A5083457840 @default.
- W2895726097 hasConcept C104317684 @default.
- W2895726097 hasConcept C126322002 @default.
- W2895726097 hasConcept C141071460 @default.
- W2895726097 hasConcept C168563851 @default.
- W2895726097 hasConcept C185592680 @default.
- W2895726097 hasConcept C197934379 @default.
- W2895726097 hasConcept C2776441376 @default.
- W2895726097 hasConcept C2776532303 @default.
- W2895726097 hasConcept C2777637488 @default.
- W2895726097 hasConcept C2778375690 @default.
- W2895726097 hasConcept C2778384902 @default.
- W2895726097 hasConcept C2779256223 @default.
- W2895726097 hasConcept C2780269544 @default.
- W2895726097 hasConcept C3019879682 @default.
- W2895726097 hasConcept C523546767 @default.
- W2895726097 hasConcept C535046627 @default.
- W2895726097 hasConcept C54355233 @default.
- W2895726097 hasConcept C547475151 @default.
- W2895726097 hasConcept C55493867 @default.
- W2895726097 hasConcept C71924100 @default.
- W2895726097 hasConcept C86803240 @default.
- W2895726097 hasConceptScore W2895726097C104317684 @default.
- W2895726097 hasConceptScore W2895726097C126322002 @default.
- W2895726097 hasConceptScore W2895726097C141071460 @default.
- W2895726097 hasConceptScore W2895726097C168563851 @default.
- W2895726097 hasConceptScore W2895726097C185592680 @default.
- W2895726097 hasConceptScore W2895726097C197934379 @default.
- W2895726097 hasConceptScore W2895726097C2776441376 @default.
- W2895726097 hasConceptScore W2895726097C2776532303 @default.
- W2895726097 hasConceptScore W2895726097C2777637488 @default.